Management of aplastic anemia: The role of systematic reviews and meta-analyses

Anat Gafter-Gvili, Ron Ram, Pia Raanani, Ofer Shpilberg

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Aplastic anemia is a rare bone marrow failure disorder. Allogeneic hematopoietic cell transplantation (alloHCT) and immunosuppressive therapy (IST) are the main therapeutic modalities currently used to treat patients with aplastic anemia. Systematic reviews and meta-analyses of randomized controlled trials (RCTs) are regarded as the highest level of evidence and as such aid practitioners in solving clinical questions. The objective of this review is to assess the base of evidence for the common practice and the current guidelines for the management of aplastic anemia. It focuses on data obtained from systematic reviews and meta-analyses of RCTs conducted in this field. Specifically, it focuses on four major therapeutic questions: the roles of alloHCT, IST, hematopoietic growth factors and supportive care.

Original languageEnglish
Pages (from-to)47-54
Number of pages8
JournalActa Haematologica
Issue number1-2
StatePublished - Dec 2010
Externally publishedYes


  • Allogeneic transplantation
  • Antithymocyte globulin
  • Aplastic anemia
  • Cyclosporine
  • Hematopoietic growth factors
  • Meta-analysis
  • Systematic review


Dive into the research topics of 'Management of aplastic anemia: The role of systematic reviews and meta-analyses'. Together they form a unique fingerprint.

Cite this